Trials that use: Multiple imputation / missing data
New to this method? Read the tutorial →
20,324 results
- IV Ibuprofen for Post-Electroconvulsive Therapy Myalgia: Complete Statistical AnalysisIndependent statistical analysis of IV Ibuprofen for Post-Electroconvulsive Therapy Myalgia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01200069).
- IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures: Complete Statistical AnalysisIndependent statistical analysis of IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis: Complete Statistical AnalysisIndependent statistical analysis of IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- IV TylenolIndependent statistical analysis of IV vs. Oral Acetaminophen as a Component of Multimodal Analgesia After Total Hip Arthroplasty: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- iVASTIndependent statistical analysis of The Intra-arterial Vasospasm Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01996436).
- Ivermectin and Human Immunity: Complete Statistical AnalysisIndependent statistical analysis of Ivermectin and Human Immunity: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03459794).
- IVF Hyper-responders: Oocyte Vitrification Compared With Embryo Freezing: Complete Statistical AnalysisIndependent statistical analysis of IVF Hyper-responders: Oocyte Vitrification Compared With Embryo Freezing: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02026193).
- IVHIndependent statistical analysis of Tortle Midliner and Intraventricular Hemorrhage: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03543046).
- IVIDAIndependent statistical analysis of Intravenous Iron for Iron-deficiency Anemia in Pregnancy: a Randomized Controlled Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3: Complete Statistical AnalysisIndependent statistical analysis of IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03401073).
- IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy: Complete Statistical AnalysisIndependent statistical analysis of IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02697292).
- IVIG Versus Placebo for the Treatment of Patients With Severe C-Diff: Complete Statistical AnalysisIndependent statistical analysis of IVIG Versus Placebo for the Treatment of Patients With Severe C-Diff: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- ivWatch Model 400: Device Validation for Non-Infiltrated Tissues: Complete Statistical AnalysisIndependent statistical analysis of ivWatch Model 400: Device Validation for Non-Infiltrated Tissues: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02120443).
- ivWatch Sensor: Device Validation for Infiltrated Tissues: Complete Statistical AnalysisIndependent statistical analysis of ivWatch Sensor: Device Validation for Infiltrated Tissues: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04064229).
- IVYIndependent statistical analysis of A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- IWPIndependent statistical analysis of Immigrant Well-being Project: Transdisciplinary Ecological Mental Health Intervention for Mexican Immigrants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- IWWPIndependent statistical analysis of It's WeWomen Plus Intervention for Health, Safety and Empowerment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04098276).
- IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE): Complete Statistical AnalysisIndependent statistical analysis of IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Ixabepilone in Treating Patients With Metastatic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Ixabepilone in Treating Patients With Metastatic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00087139).
- Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00095979).
- Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Ixabepilone to Treat Cervical Cancer: Complete Statistical AnalysisIndependent statistical analysis of Ixabepilone to Treat Cervical Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00924066).
- Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement: Complete Statistical AnalysisIndependent statistical analysis of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib: Complete Statistical AnalysisIndependent statistical analysis of Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis: Complete Statistical AnalysisIndependent statistical analysis of Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- IXORA-RIndependent statistical analysis of A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- IXTENDIndependent statistical analysis of Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- J-MINDIndependent statistical analysis of To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL): primary endpoint results, effect estimate with…
- J-TARGET,Japanese Telmisartan Study for Antihypertensive Good Effect in Long Term Observation: Complete Statistical AnalysisIndependent statistical analysis of J-TARGET,Japanese Telmisartan Study for Antihypertensive Good Effect in Long Term Observation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- JACOBIndependent statistical analysis of A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer: primary endpoint…
- JADE MOAIndependent statistical analysis of Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- JADE Mono-1Independent statistical analysis of Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis: primary endpoint results, effect estimate with confidence…
- JADE Mono-2Independent statistical analysis of Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis: primary endpoint results, effect estimate with confidence interval,…
- JADE TEENIndependent statistical analysis of JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis: Complete Statistical AnalysisIndependent statistical analysis of JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- JAKARTAIndependent statistical analysis of Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- JakStat2Independent statistical analysis of Topical Interferon Gamma for Macular Edema Secondary to Uveitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01376362).
- Janus Kinase Inhibition in Granuloma Annulare: Complete Statistical AnalysisIndependent statistical analysis of Janus Kinase Inhibition in Granuloma Annulare: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05650736).
- Japanese AMLIndependent statistical analysis of Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Japanese IP-TN Trial: Complete Statistical AnalysisIndependent statistical analysis of Japanese IP-TN Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02831569).
- Japanese Phase 1 Trial of Sym004 in Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Japanese Phase 1 Trial of Sym004 in Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01955473).
- Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients: Complete Statistical AnalysisIndependent statistical analysis of Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD): Complete Statistical AnalysisIndependent statistical analysis of JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- JAVAIndependent statistical analysis of Purple Grape Juice in Improving Vascular Health in Childhood Cancer Survivors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…